Large amounts of weight loss can improve health dramatically, but patients may also notice changes in their skin, hair, and facial appearance. The popular term “Ozempic face” has made facial-volume loss particularly visible in public discussion, even though these changes may reflect substantial weight loss itself rather than a unique toxic effect of one medication.
A new 2026 dermatology study adds useful patient-reported data about both sides of this issue: some inflammatory skin symptoms may improve during weight-loss treatment, while skin sagging, hair loss, and decreased facial volume become more common as the amount of weight lost increases.
What the study found
Researchers surveyed 1,226 patients in a virtual cardio-kidney-metabolic treatment program and grouped responses according to the percentage of body weight lost and whether treatment involved GLP-1 receptor agonists, non-GLP-1 therapies, or combination treatment.
Among respondents who had lost more than 20% of their body weight, 72% reported skin sagging, 52% reported hair loss, and 50% reported decreased facial volume. Among those losing 10% to 20%, the corresponding figures were 44%, 30%, and 37%. Among those losing less than 10%, the rates were considerably lower: 15%, 17%, and 13%. The trends increased significantly as the percentage of weight loss increased.
Is “Ozempic face” really caused by GLP-1 medications?
The study supports a more nuanced answer than the nickname suggests. Facial-volume loss and skin laxity occurred across weight-management groups, and the magnitude of weight loss itself was strongly associated with these changes. In the 10% to 20% weight-loss category, patient-reported skin sagging and facial-volume loss were more common in the GLP-1 group than in the non-GLP-1 group, but those differences narrowed among people who lost more than 20% of body weight.
That pattern is compatible with the idea that both treatment modality and the biological consequences of substantial weight loss may contribute. Because this was an observational, patient-reported survey, it cannot establish that GLP-1 medications directly cause each cosmetic change.
What about hair loss?
Hair shedding can accompany rapid or substantial weight loss. Reduced caloric intake, inadequate protein or micronutrient intake, physiological stress, and other factors may contribute. Patients experiencing persistent or substantial hair loss should not assume the medication itself is the only explanation; nutritional intake, rate of weight loss, thyroid disease, iron status, other medications, and additional causes may need consideration.
The other side of the story: inflammatory skin disease
The report also collected patient-reported changes in inflammatory skin conditions. This is clinically interesting because obesity is associated with systemic inflammation and several dermatologic disorders. The findings suggest that weight-management treatment may coincide with improvement in some inflammatory skin symptoms for some patients. However, survey data are hypothesis-generating and should not be interpreted as proof that GLP-1 therapy is an established treatment for a particular dermatologic disease.
Can facial changes after weight loss be treated?
Treatment depends on what has changed. Neurotoxins such as Xeomin can soften dynamic lines such as forehead lines, frown lines, and crow’s feet, but they do not replace lost facial volume. Other cosmetic approaches may be appropriate when volume loss or skin laxity is the principal concern. The first step is identifying whether the issue is facial movement lines, loss of volume, skin laxity, or a combination.
How to reduce avoidable problems during major weight loss
- Aim for nutritionally adequate weight loss rather than simply the fastest possible loss.
- Make adequate protein intake a deliberate part of the treatment plan.
- Use resistance exercise to help preserve muscle and function.
- Maintain broad micronutrient coverage and evaluate specific deficiencies when clinically indicated.
- Discuss excessive appetite suppression, persistent nausea, vomiting, or inability to meet nutritional needs with the treating clinician.
- Seek medical evaluation for substantial or persistent hair loss rather than assuming it is inevitable.
BeLite Clinical Perspective
The term “Ozempic face” is catchy but medically imprecise. Substantial weight loss changes facial and body tissues regardless of how the weight is lost. The new study is useful because it quantifies how strongly patient-reported skin sagging, hair loss, and facial-volume loss rise with increasing weight loss, while also suggesting potential improvement in inflammatory skin symptoms. The practical goal should be high-quality weight loss: improve health while preserving nutrition, muscle, function, and appearance as much as reasonably possible.
Frequently Asked Questions
What does “Ozempic face” mean?
“Ozempic face” is a nonmedical term commonly used to describe facial-volume loss, increased skin laxity, or more visible facial lines after substantial weight loss. These changes are not necessarily unique to semaglutide or GLP-1 medications; loss of facial fat and tissue volume can occur with major weight loss from multiple causes.
Do GLP-1 medications directly cause loose skin or facial sagging?
The new study cannot establish that they directly cause these changes. Patient-reported skin sagging and facial-volume loss increased markedly as the percentage of weight lost increased. Some differences were seen between treatment groups, but the observational survey design cannot separate the medication effect from the effects of substantial weight loss and other factors.
Can GLP-1 treatment cause hair loss?
Hair shedding can occur during rapid or substantial weight loss, including weight loss that occurs during GLP-1 treatment. Potential contributors include reduced calorie or protein intake, micronutrient deficiency, physiological stress, thyroid disease, iron deficiency, other medications, and other causes. Persistent or substantial hair loss deserves clinical evaluation rather than being automatically attributed to the GLP-1 medication.
Can GLP-1 medications improve inflammatory skin conditions?
The 2026 study found patient-reported improvement in some inflammatory skin symptoms during weight-management treatment, which is clinically interesting. However, the study was observational and survey-based. It does not establish GLP-1 medications as approved or proven treatments for a specific inflammatory skin disease.
Can Xeomin restore facial volume lost after weight loss?
No. Xeomin is a botulinum toxin product used to soften dynamic facial lines caused by muscle movement, such as frown lines or forehead lines. It does not replace lost facial volume. Patients concerned about post-weight-loss facial changes should first determine whether the main issue is dynamic wrinkles, volume loss, skin laxity, or a combination.
Related BeLite Resources
How BeLite Can Help
BeLite Medical Center provides medically supervised weight management and can help patients balance efficacy with tolerability, nutrition, exercise, and long-term maintenance. BeLite also offers Xeomin for appropriate patients who want treatment of dynamic facial lines that may become more noticeable after weight loss.
Learn more about BeLite Medical Center and schedule a free consultation.
References
Rao S, et al. Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face.” Dermatology and Therapy. Published August 11, 2026.
BeLite can help patients translate emerging obesity-medicine evidence into an individualized plan that considers efficacy, tolerability, nutrition, muscle preservation, long-term maintenance, and access.BeLite Medical Center has provided physician-supervised medical weight management in Fairfax, Virginia since 1995. Our clinic offers in-person medical supervision — with the ability to adjust medications and monitor your progress in real time — that fully virtual services cannot match.Booking appointments is simple with our online scheduling portal, available 24/7. You can also call or text us at (703) 359-9200, or email belitemed@gmail.com. We offer free consultations for new patients — if you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time
Medical Disclaimer
This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the readers own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.
Reviewed by Richard Rothman, MD, PhD — Medical Director, BeLite Medical Center.
